Literature DB >> 22138963

Is KRAS mutation associated with interval colorectal cancers?

Aasma Shaukat1, Mustafa Arain, Ruth Anway, Sharad Manaktala, Laurie Pohlman, Bharat Thyagarajan.   

Abstract

BACKGROUND: Colorectal cancers diagnosed in the interval after a complete colonoscopy may occur due to rapid tumor growth. Interval colorectal cancers are associated with microsatellite instability (MSI). AIMS: Our aim was to study the association of KRAS mutation with interval colorectal cancers and MSI.
METHODS: We searched our institution's cancer registry for interval colorectal cancers, defined as colorectal cancers that developed within 5 years of a complete colonoscopy. These were frequency matched to patients with non-interval colorectal cancers. Archived cancer specimens were evaluated for KRAS mutations in codons 12 and 13 using sequencing, and MSI by sequencing microsatellite loci. Multivariable logistic regression was used to analyze the association between KRAS mutation status, MSI status and interval colorectal cancers.
RESULTS: There were 63 interval and 131 non-interval colorectal cancers. KRAS mutation was present in 12.9% of interval cancers compared to 28.9% of non-interval cancers (P = 0.03). In multivariable logistic regression model, KRAS was inversely associated with interval cancers (OR 0.36; 95% CI 0.15-0.90). In Cox proportional hazards model, adjusting for age, tumor grade, TNM Stage and MSI status, we found no association between KRAS mutation and 5-year survival compared to cancers without KRAS mutation (HR 0.84; 95% CI 0.4-1.46; P = 0.5).
CONCLUSIONS: KRAS mutation is inversely associated with interval cancers and with MSI, suggesting that it is a marker of the chromosomal instability pathway associated with slow tumor growth, and distinct from MSI rapidly growing cancers. Molecular characterization of colorectal cancers is helpful in determining underlying pathway and may determine therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22138963     DOI: 10.1007/s10620-011-1974-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  11 in total

1.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.

Authors:  Shuji Ogino; Katsuhiko Nosho; Gregory J Kirkner; Takako Kawasaki; Jeffrey A Meyerhardt; Massimo Loda; Edward L Giovannucci; Charles S Fuchs
Journal:  Gut       Date:  2008-10-02       Impact factor: 23.059

Review 2.  Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis.

Authors:  A Walther; R Houlston; I Tomlinson
Journal:  Gut       Date:  2008-03-25       Impact factor: 23.059

3.  CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.

Authors:  Shuji Ogino; Jeffrey A Meyerhardt; Takako Kawasaki; Jeffrey W Clark; David P Ryan; Matthew H Kulke; Peter C Enzinger; Brian M Wolpin; Massimo Loda; Charles S Fuchs
Journal:  Virchows Arch       Date:  2007-03-20       Impact factor: 4.064

Review 4.  The chromosomal instability pathway in colon cancer.

Authors:  Maria S Pino; Daniel C Chung
Journal:  Gastroenterology       Date:  2010-06       Impact factor: 22.682

5.  CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability.

Authors:  Nicholas Hawkins; Mark Norrie; Kay Cheong; Elisa Mokany; Su-Lyn Ku; Alan Meagher; Terence O'Connor; Robyn Ward
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

6.  KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis.

Authors:  Xiuli Liu; Maureen Jakubowski; Jennifer L Hunt
Journal:  Am J Clin Pathol       Date:  2011-02       Impact factor: 2.493

7.  Is BRAF mutation associated with interval colorectal cancers?

Authors:  Aasma Shaukat; Mustafa Arain; Bharat Thaygarajan; John H Bond; Mandeep Sawhney
Journal:  Dig Dis Sci       Date:  2010-03-19       Impact factor: 3.199

8.  Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers.

Authors:  Wade S Samowitz; Carol Sweeney; Jennifer Herrick; Hans Albertsen; Theodore R Levin; Maureen A Murtaugh; Roger K Wolff; Martha L Slattery
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

9.  Microsatellite instability in interval colon cancers.

Authors:  Mandeep S Sawhney; William D Farrar; Srivani Gudiseva; Douglas B Nelson; Frank A Lederle; Thomas S Rector; John H Bond
Journal:  Gastroenterology       Date:  2006-12       Impact factor: 22.682

10.  High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.

Authors:  Daniele Santini; Fotios Loupakis; Bruno Vincenzi; Irene Floriani; Irene Stasi; Emanuele Canestrari; Eliana Rulli; Paolo Enrico Maltese; Francesca Andreoni; Gianluca Masi; Francesco Graziano; Giacomo Giulio Baldi; Lisa Salvatore; Antonio Russo; Giuseppe Perrone; Maria Rosa Tommasino; Mauro Magnani; Alfredo Falcone; Giuseppe Tonini; Annamaria Ruzzo
Journal:  Oncologist       Date:  2008-12-04
View more
  10 in total

Review 1.  Interval colorectal cancers: what and why.

Authors:  Chantal M C le Clercq; Silvia Sanduleanu
Journal:  Curr Gastroenterol Rep       Date:  2014-03

2.  The contribution of endoscopy quality measures to the development of interval colorectal cancers in the screening population: a systematic review.

Authors:  Deirdre M Nally; Athena Wright Ballester; Gintare Valentelyte; Dara O Kavanagh
Journal:  Int J Colorectal Dis       Date:  2018-10-29       Impact factor: 2.571

3.  Genetic mechanisms in interval colon cancers.

Authors:  James M Richter; Maria Simona Pino; Thomas R Austin; Emily Campbell; Jackie Szymonifka; Andrea L Russo; Theodore S Hong; Darrell Borger; A John Iafrate; Daniel C Chung
Journal:  Dig Dis Sci       Date:  2014-04-05       Impact factor: 3.199

Review 4.  Establishing a biological profile for interval colorectal cancers.

Authors:  Amy L Cisyk; Harminder Singh; Kirk J McManus
Journal:  Dig Dis Sci       Date:  2014-05-20       Impact factor: 3.199

5.  Characterizing the prevalence of chromosome instability in interval colorectal cancer.

Authors:  A L Cisyk; S Penner-Goeke; Z Lichtensztejn; Z Nugent; R H Wightman; H Singh; K J McManus
Journal:  Neoplasia       Date:  2015-03       Impact factor: 5.715

6.  Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype.

Authors:  Y Zhu; S R Yang; P P Wang; S Savas; T Wish; J Zhao; R Green; M Woods; Z Sun; B Roebothan; J Squires; S Buehler; E Dicks; J Zhao; J R Mclaughlin; P S Parfrey; P T Campbell
Journal:  Br J Cancer       Date:  2014-01-21       Impact factor: 7.640

7.  Interval cancers in a population-based screening program for colorectal cancer in catalonia, Spain.

Authors:  M Garcia; X Domènech; C Vidal; E Torné; N Milà; G Binefa; L Benito; V Moreno
Journal:  Gastroenterol Res Pract       Date:  2015-02-24       Impact factor: 2.260

8.  Characterizing Microsatellite Instability and Chromosome Instability in Interval Colorectal Cancers.

Authors:  Amy L Cisyk; Zoann Nugent; Robert H Wightman; Harminder Singh; Kirk J McManus
Journal:  Neoplasia       Date:  2018-08-15       Impact factor: 5.715

9.  Long-term colorectal-cancer incidence and mortality after lower endoscopy.

Authors:  Reiko Nishihara; Kana Wu; Paul Lochhead; Teppei Morikawa; Xiaoyun Liao; Zhi Rong Qian; Kentaro Inamura; Sun A Kim; Aya Kuchiba; Mai Yamauchi; Yu Imamura; Walter C Willett; Bernard A Rosner; Charles S Fuchs; Edward Giovannucci; Shuji Ogino; Andrew T Chan
Journal:  N Engl J Med       Date:  2013-09-19       Impact factor: 91.245

10.  Frequency and Characteristics of Interval Colorectal Cancer in Actual Clinical Practice: A KASID Multicenter Study.

Authors:  Kyeong Ok Kim; Kyu Chan Huh; Sung Pil Hong; Won Hee Kim; Hyuk Yoon; Sang Wook Kim; Yeon Soo Kim; Jong Ha Park; Jun Lee; Bum Jae Lee; Young Sook Park
Journal:  Gut Liver       Date:  2018-09-15       Impact factor: 4.519

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.